Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

A Novel Role for HMGN1 in Down Syndrome Acute Lymphoblastic Leukemia

Elyse C Page, BSc, Susan L Heatley, PhD MD, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Paul Q Thomas, PhD, Deborah L. White, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 1462.

https://doi.org/10.1182/blood-2019-126244

Published: 2019

Journal Articles

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Blood (2019) 134 (Supplement_1): 1351.

https://doi.org/10.1182/blood-2019-126523

Published: 2019

Journal Articles

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

Blood (2019) 134 (Supplement_1): 4150.

https://doi.org/10.1182/blood-2019-127619

Published: 2019

Journal Articles

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Jacqueline Rhen, BSc MSc MD, Susan L Heatley, PhD MD, Barbara McClure, BSc (Hons) PhD, Laura N Eadie, BSc (Hons) PhD, Jimmy Breen, BSc (Hons) PhD, Caitlin Schutz Schutz, BSc (Hons), Toby N Trahair, MBBS FRACP PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Luciano Dalla-Pozza, MBBS FRACP, Rosemary Sutton, BSc MSc PhD, Kenneth F Bradstock, BSc(MD, MBBS, PhD FRACP, FRCPA, Michael Philip Osborn, MB, BS, Deborah L. White, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 3949.

https://doi.org/10.1182/blood-2019-127788

Published: 2019

Journal Articles

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Nadia El Khawanky, Bsc(Biomed), BHlthSc(Hons), Amy Hughes, PhD, Wenbo Yu, PhD, Sanaz Taromi, PhD, Jade Clarson, BSc, Angel F. Lopez, MD PhD, Michael P. Brown, MD PhD, Justus Duyster, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Deborah L. White, PhD FFSc (RCPA), Agnes S. M. Yong, MD PhD, Robert Zeiser, MD

Blood (2019) 134 (Supplement_1): 3904.

https://doi.org/10.1182/blood-2019-124684

Published: 2019

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Blood (2019) 134 (Supplement_1): 2926.

https://doi.org/10.1182/blood-2019-125740

Published: 2019

Journal Articles

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Blood (2017) 130 (Supplement 1): 2898.

https://doi.org/10.1182/blood.V130.Suppl_1.2898.2898

Published: 2017

Journal Articles

Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen-Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling

Amy Hughes, PhD, Jade Clarson, Deborah L White, PhD FFSc (RCPA), David Yeung, PhDBSc,FRACP,FRCPA,MBBS, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Agnes S. M. Yong, MDPhD

Blood (2017) 130 (Supplement 1): 1581.

https://doi.org/10.1182/blood.V130.Suppl_1.1581.1581

Published: 2017

Journal Articles

Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)

David M Ross, MBBS, PhD FRACP, FRCPA, Ilaria S Pagani, PhD, Naranie Shanmuganathan, MBBS, John F Seymour, MBBS, PhD, Anthony K Mills, FRACP, FRCPA, MBBS, Robin J Filshie, PhDFRACP,FRCPA, Christopher K Arthur, MDFRACP,FRCPA,MBBS, Phuong Dang, Verity A Saunders, Jody Braley, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Deborah L White, PhD FFSc (RCPA), Andrew P Grigg, MBBS, MD FRACP, FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Susan Branford, PhD, Timothy P. Hughes, MD

Blood (2017) 130 (Supplement 1): 1597.

https://doi.org/10.1182/blood.V130.Suppl_1.1597.1597

Published: 2017

Journal Articles

Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation

Amy Hughes, PhD, Jade Clarson, B.Sc, Deborah L White, PhD FFSc (RCPA), David M. Ross, MBBS, PhD FRACP, FRCPA, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Agnes S Yong, MD PhD

Blood (2016) 128 (22): 1122.

https://doi.org/10.1182/blood.V128.22.1122.1122

Published: 2016

Journal Articles

A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells

Verity A Saunders, BSc (Hons), Jueqiong Wang, PhD, Liu Lu, PhD, Laura N Eadie, PhD, Jennifer A McLean, Jarrad M Goyne, BMedSc (Hons), David T. Yeung, BSc, MBBS, FRACP, FRCPA, Deborah L White, PhD FFSc (RCPA), Timothy P Hughes, MD FRACP, FRCPA, MBBS

Blood (2016) 128 (22): 1121.

https://doi.org/10.1182/blood.V128.22.1121.1121

Published: 2016

Journal Articles

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Blood (2016) 128 (22): 939.

https://doi.org/10.1182/blood.V128.22.939.939

Published: 2016

Journal Articles

The ABCC6 Transporter Plays a Significant Role in the Efflux of Nilotinib and Dasatinib, and May Contribute to Tyrosine Kinase Inhibitor Resistance

Laura N Eadie, PhD, Jarrad M Goyne, BMedSc (Hons), Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Deborah L White, PhD FFSc (RCPA)

Blood (2016) 128 (22): 4237.

https://doi.org/10.1182/blood.V128.22.4237.4237

Published: 2016

Journal Articles

In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy

Kartini Asari, Susan L Heatley, PhD MD, Teresa Sadras, PhD, Tamara M Leclercq, PhD, Stephen Fitter, PhD, Chung Hoow Kok, PhD, Andrew C W Zannettino, PhD, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, Deborah L White, PhD FFSc (RCPA)

Blood (2016) 128 (22): 3957.

https://doi.org/10.1182/blood.V128.22.3957.3957

Published: 2016

Journal Articles

High Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells

Jueqiong WANG, PhD, Chung Hoow Kok, PhD, Tamara M Leclercq, PhD, Verity A Saunders, BSc (Hons), Richard J D'Andrea, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Deborah L White, PhD FFSc (RCPA)

Blood (2015) 126 (23): 2770.

https://doi.org/10.1182/blood.V126.23.2770.2770

Published: 2015

Journal Articles

A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib

Chung Hoow Kok, PhD, Tamara M Leclercq, PhD, Dale Watkins, PhD, David T Yeung, BSc, MBBS, FRACP, FRCPA, Verity A Saunders, BSc (Hons), Deborah L White, PhD FFSc (RCPA), Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 596.

https://doi.org/10.1182/blood.V126.23.596.596

Published: 2015

Journal Articles

High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment

Blood (2015) 126 (23): 1419.

https://doi.org/10.1182/blood.V126.23.1419.1419

Published: 2015

Journal Articles

The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2

Laura N Eadie, PhD, Verity A Saunders, BSc (Hons), Tamara M Leclercq, PhD, Susan Branford, PhDFFSc (RCPA), Deborah L White, PhD FFSc (RCPA), Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 4841.

https://doi.org/10.1182/blood.V126.23.4841.4841

Published: 2015

Journal Articles

The Clinical Significance of Early Imatinib Induced ABCB1 Overexpression in Chronic Phase CML Patients: A TIDEL II Sub-Study

Laura N Eadie, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Deborah L White, PhD FFSc (RCPA)

Blood (2015) 126 (23): 348.

https://doi.org/10.1182/blood.V126.23.348.348

Published: 2015

Journal Articles

Modeling Ponatinib Resistance in BCR-ABL1 + Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naïve Patients

Liu Lu, BscHons, Verity Saunders, BScHons, Chung H Kok, PhD, Tamara Leclercq, PhD, Timothy P Hughes, MD MBBS, FRACP, FRCPA, Deborah L White, PhD FFSc (RCPA)

Blood (2014) 124 (21): 4515.

https://doi.org/10.1182/blood.V124.21.4515.4515

Published: 2014

NARROW

A Novel Role for HMGN1 in Down Syndrome Acute Lymphoblastic Leukemia

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen-Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling

Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)

Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation

A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

The ABCC6 Transporter Plays a Significant Role in the Efflux of Nilotinib and Dasatinib, and May Contribute to Tyrosine Kinase Inhibitor Resistance

In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy

High Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells

A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib

High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment

The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2

The Clinical Significance of Early Imatinib Induced ABCB1 Overexpression in Chronic Phase CML Patients: A TIDEL II Sub-Study

Modeling Ponatinib Resistance in BCR-ABL1 + Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naïve Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only